Payment overview · 2025
General Payments
$405.46
24 reported records · 10 companies
Healthcare provider profile · identity verified
Richard Boyles, MD
Allopathic & Osteopathic Physicians|Family Medicine · BLACKVILLE, SC · NPI 1003820531
Verified facts
What the public records show
CMS Open Payments records show Richard Boyles, MD received $405.46 in general payments during 2025 across 24 reported records.
ABBVIE INC. accounted for 39.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $159.12 | 39.2% | 11 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $78.08 | 19.3% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.63 | 8.8% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.69 | 6.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $23.82 | 5.9% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $21.46 | 5.3% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.10 | 5.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.17 | 3.7% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $14.34 | 3.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $12.05 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $405.46 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $159.12 | 11 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $60.22 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.69 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.82 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $23.82 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $21.46 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.17 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $12.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 230 | 32 |
| Alprazolam | Alprazolam | 190 | 26 |
| Clonazepam | Clonazepam | 170 | 35 |
| Amlodipine Besylate | Amlodipine Besylate | 162 | 48 |
| Atorvastatin Calcium | Atorvastatin Calcium | 152 | 43 |
| Tramadol Hcl | Tramadol Hcl | 145 | 26 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 144 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 130 | 33 |
| Levothyroxine Sodium | Levothyroxine Sodium | 129 | 37 |
| Losartan Potassium | Losartan Potassium | 125 | 37 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 120 | 34 |
| Gabapentin | Gabapentin | 112 | 37 |
| Omeprazole | Omeprazole | 106 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 104 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 101 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 98 | 19 |
| Trazodone Hcl | Trazodone Hcl | 90 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 86 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 85 | 29 |
| Prednisone | Prednisone | 84 | 50 |
| Azithromycin | Azithromycin | 78 | 61 |
| Montelukast Sodium | Montelukast Sodium | 73 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 64 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 17 |
| Oxycodone Hcl | Oxycodone Hcl | 63 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 62 | 17 |
| Famotidine | Famotidine | 62 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 27 |
| Pregabalin | Pregabalin | 60 | 14 |
| Eliquis | Apixaban | 59 | 13 |
| Metformin Hcl | Metformin Hcl | 58 | 20 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 55 | 17 |
| Mounjaro | Tirzepatide | 55 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 51 | 19 |
| Furosemide | Furosemide | 51 | 24 |
| Ozempic | Semaglutide | 51 | suppressed |
| Allopurinol | Allopurinol | 50 | 18 |
| Diazepam | Diazepam | 49 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 49 | 34 |
| Meclizine Hcl | Meclizine Hcl | 47 | 18 |
| Potassium Chloride | Potassium Chloride | 43 | 12 |
| Meloxicam | Meloxicam | 42 | 14 |
| Jardiance | Empagliflozin | 41 | suppressed |
| Carisoprodol | Carisoprodol | 40 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 40 | suppressed |
| Lisinopril | Lisinopril | 39 | suppressed |
| Methocarbamol | Methocarbamol | 39 | 13 |
| Valsartan | Valsartan | 38 | 11 |
| Carvedilol | Carvedilol | 37 | 15 |
| Lorazepam | Lorazepam | 37 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | suppressed |
| Simvastatin | Simvastatin | 35 | 11 |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Rybelsus | Semaglutide | 31 | suppressed |
| Fentanyl | Fentanyl | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 23 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 29 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 19 |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 25 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Mirtazapine | Mirtazapine | 23 | suppressed |
| Vraylar | Cariprazine Hcl | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 20 | suppressed |
| Celecoxib | Celecoxib | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 15 |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 15 |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Spironolactone | Spironolactone | 14 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 14 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Naratriptan Hcl | Naratriptan Hcl | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Perphenazine-Amitriptyline | Perphenazine/Amitriptyline Hcl | 13 | suppressed |
| Quviviq | Daridorexant Hcl | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Finasteride | Finasteride | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $405.46 · 24 records | ABBVIE INC. | APRETUDE, Auvelity, BREZTRI, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, GARDASIL 9, Ozempic, Rybelsus, SUBLOCADE, The Cologuard Plus Collection Kit, VRAYLAR, Veozah | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error